Jump Financial, LLC Biomea Fusion, Inc. Transaction History

Jump Financial, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$4.23 - $10.1 $45,684 - $109,080	-10,800 Closed	0 $0
Q2 2024 Aug 14, 2024	SELL	$4.14 - $15.3 $3,643 - $13,464	-880 Reduced 7.53%	10,800 $48,000
Q1 2024 May 13, 2024	SELL	$13.92 - $19.5 $265,858 - $372,430	-19,099 Reduced 62.05%	11,680 $174,000
Q4 2023 Oct 21, 2024	SELL	$8.37 - $19.8 $99,912 - $236,352	-11,937 Reduced 27.95%	30,779 $446,000
Q4 2023 Feb 07, 2024	SELL	$8.37 - $19.8 $99,912 - $236,352	-11,937 Reduced 27.95%	30,779 $446,000
Q3 2023 Oct 21, 2024	SELL	$13.44 - $23.02 $710,398 - $1.22 Million	-52,857 Reduced 55.31%	42,716 $587,000
Q3 2023 Nov 07, 2023	SELL	$13.44 - $23.02 $710,398 - $1.22 Million	-52,857 Reduced 55.31%	42,716 $587,000
Q2 2023 Oct 21, 2024	BUY	$21.66 - $41.8 $1.84 Million - $3.54 Million	84,773 Added 784.94%	95,573 $2.1 Million
Q2 2023 Aug 07, 2023	BUY	$21.66 - $41.8 $2.07 Million - $3.99 Million	95,573 New	95,573 $2.1 Million
Q1 2022 May 12, 2022	SELL	$4.39 - $9.03 $72,435 - $148,995	-16,500 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$7.22 - $12.72 $119,130 - $209,880	16,500 New	16,500 $123,000

104

17.9M

1.68M

410K

Ticker BMEA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,290,600
Market Cap $122M
Description
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.